{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:30:28Z","timestamp":1793457028039,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106600","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:58:17Z","timestamp":1753372697000},"page":"106600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world experience with cladribine in the two years since treatment start: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-5392","authenticated-orcid":false,"given":"Angela","family":"Albanese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106600_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578164","article-title":"Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers","volume":"382","author":"Adamec","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106600_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104735","article-title":"Safety and effectiveness of cladribine tablets for multiple sclerosis: results from a single-center real-world cohort","volume":"75","author":"Aerts","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.msard.2025.106600_bib0003","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/1570159X21666230322140711","article-title":"Real-world effectiveness of Cladribine for patients with multiple sclerosis: a Sicilian multicentric experience (Rewind Study)","volume":"22","author":"Arena","year":"2023","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"10.1016\/j.msard.2025.106600_bib0004","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.msard.2025.106600_bib0005","unstructured":"Cladribine - StatPearls - NCBI Bookshelf. (n.d.)."},{"key":"10.1016\/j.msard.2025.106600_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.phrs.2016.09.003","article-title":"Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors","volume":"113","author":"Chiurchi\u00f9","year":"2016","journal-title":"Pharmacol Res."},{"issue":"2","key":"10.1016\/j.msard.2025.106600_bib0006","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing\u2013Remitting multiple sclerosis: a clinician\u2019s review","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.msard.2025.106600_bib0007","first-page":"113","article-title":"Comparative effectiveness studies in multiple sclerosis","volume":"10","author":"Hersh","year":"2020"},{"key":"10.1016\/j.msard.2025.106600_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577966","article-title":"Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4","volume":"372","author":"Magalashvili","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106600_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/nmt-2021-0041","article-title":"Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary","volume":"12","author":"Oh","year":"2022","journal-title":"Neurodegener Dis Manag"},{"issue":"3","key":"10.1016\/j.msard.2025.106600_bib0010","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40120-022-00364-6","article-title":"Predictors of cladribine effectiveness and safety in Multiple sclerosis: a real-world, multicenter, 2-year follow-up study","volume":"11","author":"Petracca","year":"2022","journal-title":"Neurol Ther"},{"issue":"2","key":"10.1016\/j.msard.2025.106600_bib0011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2025.106600_bib0012","first-page":"61","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","author":"Rauma","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106600_bib0013","unstructured":"Santos 2023. (n.d.)."},{"issue":"3","key":"10.1016\/j.msard.2025.106600_bib0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/WNF.0000000000000552","article-title":"Safety and effectiveness of Cladribine in Multiple sclerosis: real-world clinical experience from 5 tertiary hospitals in Portugal","volume":"46","author":"Santos","year":"2023","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.msard.2025.106600_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105052","article-title":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","volume":"79","author":"Song","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106600_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104491","article-title":"Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: a Danish nationwide study","volume":"70","author":"Sorensen","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106600_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231211077","article-title":"Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response","volume":"16","author":"Teschner","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"10.1016\/j.msard.2025.106600_bib0018","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","article-title":"Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing\u2013remitting multiple sclerosis patients: a monocentric longitudinal observational study","volume":"270","author":"Zanetta","year":"2023","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:21:21Z","timestamp":1774999281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":19,"alternative-id":["S2211034825003426"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106600","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with cladribine in the two years since treatment start: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106600"}}